Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

MissionIRNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Charts Dual-Path for NRX-100 

Posted on July 18, 2025 by MissionIR

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, is accelerating its push toward regulatory approval of NRX-100, a preservative-free intravenous ketamine formulation. “The company recently filed an application under the newly created FDA Commissioner’s National Priority Voucher (‘CNPV’) program, which promises significantly shortened review timelines for drugs that meet urgent U.S. health priorities,” reads an article discussing NRx. “In parallel, the company has filed an Abbreviated New Drug Application (‘ANDA’) for NRX-100 with a request for priority review. The two pathways, CNPV and ANDA, are expected to complement one another. Should the CNPV be granted, the drug could enter a Commissioner-led review program with integrated oversight from key FDA offices.” 

To view the full article, visit https://ibn.fm/I0kJT 

About NRx Pharmaceuticals Inc. 

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. 

NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the U.S. National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the U.S. FDA as part of a protocol to treat patients with acute suicidality. 

NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment

D-Wave Quantum Inc. (NYSE: QBTS) Secures $400 Million in Equity Offering, Eyes Acquisitions and Expansion

Posted on July 18, 2025 by MissionIR
  • The $400M at-the-market equity offering was completed in just over two weeks.
  • The average sale price in the offering was at a 149% premium compared to the company’s previous ATM raise in January 2025.
  • The company holds a cash balance of approximately $815 million as of July 1.
  • Proceeds will support strategic acquisitions, capital expenditures, and working capital needs.
  • The ATM program comes as D-Wave’s Q1 2025 revenue surged 509% year-over-year, boosted by a major system sale to Germany’s Julich Supercomputing Center.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, has completed sales of $400 million in gross proceeds of its common stock in an at-the-market equity (“ATM”) offering, a move that strengthens its financial position as the company looks to scale operations and pursue strategic acquisitions. The raise, conducted between June 11 and June 27, was priced at an average of $15.18 per share. This represents a $9.08 or 149% premium to the $6.10 average price per share of the previous $150 million ATM program completed in January, according to the company (https://ibn.fm/AYkup).

This latest capital infusion brings D-Wave’s cash balance to roughly $815 million as of July 1. The company intends to use the proceeds from this financing primarily for strategic acquisitions and general corporate purposes including additional working capital and capital expenditures. 

“We intend to invest in acquisitions and programs that will enable us to expand our already significant lead as the only commercial quantum computing company with applications in production,” said Dr. Alan Baratz, CEO of D-Wave.

For the first quarter of 2025, the company reported a 509% year-over-year revenue increase, driven in large part by sale of its Advantage2(TM) quantum system to the Julich Supercomputing Center in Germany. The company has a hybrid business model, combining high-value hardware sales with a growing subscription base for its Quantum Computing-as-a-Service (“QCaaS”) platform. In Q1, D-Wave also posted a GAAP gross margin of 92.5% and achieved its lowest net loss since going public.

D-Wave remains the only commercial quantum computing company with applications in production, a position it continues to emphasize. The company’s cash position provides D-Wave flexibility to execute on its goals without near-term capital constraints. 

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our quantum computers — the world’s largest — feature QPUs with sub-second response times and can be deployed on-premises or accessed through our quantum cloud service, which offers 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our quantum systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in D-Wave Quantum Inc. QBTS | Leave a comment

MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Sets Key Dates for 25% Preferred Stock Dividend

Posted on July 18, 2025 by MissionIR

Nutriband (NASDAQ: NTRB) is reminding shareholders of its upcoming 25% preferred stock dividend. Shareholders of record as of July 25, 2025, will receive one preferred share for every four common shares held, with the dividend payable on August 5. Each preferred share will be convertible to one common share upon FDA approval of Nutriband’s AVERSA Fentanyl product. Unconverted preferred shares will be eligible for annual cash dividends from company profits at the discretion of the board.

To view the full report, visit https://ibn.fm/LsLzM

About Nutriband Inc.

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA(TM) abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information about the company, visit www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Nutriband Inc. NTRB | Leave a comment

Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial

Posted on July 18, 2025 by MissionIR
  • Recent data indicates Soligenix’s HyBryte(TM) is showing promising treatment success in early-stage cutaneous T-cell lymphoma.
  • “With limited treatment options, especially in the early stages of their disease, CTCL patients are often searching for alternative treatments,” leading investigator states.
  • No new FDA-approved, skin-directed therapies have been introduced in more than a decade, and conventional options carry risks.

Soligenix (NASDAQ: SNGX) is reporting encouraging interim outcomes from the ongoing investigator-initiated study (“IIS”) of its HyBryte(TM) (synthetic hypericin) program, under the direction of Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program. Kim is a leading enroller in Soligenix’s phase 3 FLASH study and serves as principal investigator for the confirmatory phase 3 FLASH2 trial, which recent data from the IIS indicates is delivering promising treatment success in early-stage cutaneous T-cell lymphoma (“CTCL”).

Soligenix and the Cutaneous Lymphoma Foundation recently released interim results from the open-label IIS evaluating extended HyBryte(TM) therapy administered twice weekly for up to 54 weeks in patients with early-stage mycosis fungoides (https://ibn.fm/IUoEe). At the 18-week evaluation point, six out of eight evaluable patients — 75% — achieved “treatment success,” defined as a ≥50% reduction in modified Composite Assessment of Index Lesion Severity (“mCAILS”) from baseline. This aligns with the efficacy observed in the phase 3 FLASH study, in which the response rate reached 49% (p < 0.0001 vs. placebo) after 18 weeks (https://ibn.fm/HfwFF).

Further highlighting the treatment’s speed and durability, four of the responding patients in the IIS continued on treatment through 54 weeks, achieving an average maximum mCAILS improvement of 85%, while three remained on therapy. The tolerability profile has been similarly strong: HyBryte(TM) is non-mutagenic, does not damage DNA and is not systemically absorbed; in addition, no serious adverse events or patient dropouts have been reported.

“The complete response rates observed, including three patients achieving a complete response on this study to date, as well as the consistent treatment response and safety profile across multiple HyBryte(TM) clinical studies, has been exciting to see,” said Kim. “In the first phase 3 FLASH study, HyBryte(TM) was shown to be efficacious with a benign safety profile compared to the current therapies of steroids, chemotherapeutics and ultraviolet light in this chronic orphan disease.

“With limited treatment options, especially in the early stages of their disease, CTCL patients are often searching for alternative treatments,” Kim continued. “In our study funded by the U.S. Food and Drug Administration (“FDA”), initial results evaluating the expanded use of HyBryte(TM) in a ‘real-world’ treatment setting remain very promising, further supporting and extending results from the previous positive phase 2 and 3 clinical trials. It also provides further confidence to the potential responses we can expect to see in the confirmatory phase 3 placebo-controlled FLASH2 study.”

The FLASH2 trial, a randomized, double-blind, placebo-controlled phase 3 study enrolling approximately 80 early-stage CTCL patients across the United States and Europe, began enrolling in December 2024. It extends treatment in a single continuous 18-week cycle, compared to the 6-week cycle in the original FLASH protocol, with primary efficacy assessed at week 18. Soligenix anticipates an interim analysis in early 2026.

The urgency for innovation in CTCL is clear: no new FDA-approved, skin-directed therapies have been introduced in more than a decade, and conventional options carry risks such as contact dermatitis, UV-induced skin damage and long-term carcinogenic potential (https://ibn.fm/05o9S). “CTCL patients are often searching for alternative treatment,” Kim noted. “HyBryte(TM) offers a distinct treatment option, which patients found extremely useful and continue to specifically request” (https://ibn.fm/XqgT0).

Soligenix anticipates submitting a New Drug Application (“NDA”) to the FDA following successful FLASH2 results. Kim’s leadership, combined with her pivotal role in both enrolment and oversight of these trials, positions HyBryte(TM) as a leading candidate in addressing a significant unmet need in early-stage CTCL. With FLASH2 well underway and key milestones expected in 2026, HyBryte(TM) may soon redefine treatment standards for mycosis fungoides, offering new hope to patients and investors alike.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Soligenix Inc. SNGX | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22

Posted on July 18, 2025 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company focused on treating brain and CNS cancers, will implement a 1-for-12 reverse stock split effective July 22, 2025. Its common stock will continue trading under the symbol CNSP but with a new CUSIP number: 18978H508. Each 12 shares of common stock will convert into one, with proportional adjustments to warrants and equity awards. No fractional shares will be issued—holders will receive cash instead. The authorized share count will be reduced to 25 million, while par value remains $0.001. The move is designed to affect all shareholders uniformly.

To view the full press release, visit https://ibn.fm/zB8oq

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Key Part of Five-Step Blueprint for a Balanced Rare-Earth Supply Chain

Posted on July 17, 2025 by MissionIR
  • China’s move exposed how important it is that the United States focus on finding strong domestic sources for essential materials.
  • A possible roadmap comes down to five mutually reinforcing steps, with Ucore Rare Metals’ RapidSX(TM) technology playing a key role in the process.
  • The company’s goal is to play a vital role in building a robust and independent rare earth supply chain in North America, says CEO.

The tariff war between the United States and other countries, particularly China, has created a greater awareness of the tenuous U.S. position in terms of its reliance on China for essential materials for key products. That became even clearer earlier this year when China imposed export licensing restrictions on seven medium and heavy rare-earth elements — specifically samarium, gadolinium, terbium, dysprosium, lutetium, scandium and yttrium — as retaliation for U.S. tariffs, significantly tightening the supply of elements critical for aerospace, defense and other industries (https://ibn.fm/HYY5u).

China’s move exposed how quickly one regulatory dial, controlled half a world away, can grind American production to a halt — and how important it is that the United States focus on finding strong domestic sources for essential materials. Enter Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a North America–based uranium mining and exploration company.

While there’s no single fix to securing North America’s critical metals industry, a coherent roadmap may be emerging. The plan comes down to five mutually reinforcing steps, with Ucore Rare Metals’ RapidSX(TM) technology playing a key role in the process.

The first step is to diversify the rock, or widen the funnel of ore. Exploration programs in North America and allied nations are racing to qualify fresh deposits of dysprosium, terbium and other heavy rare earths. Since 2020, the U.S. Department of Defense has committed more than $439 million to strengthen domestic rare-earth supply chains — covering mining, separation, processing and magnet manufacturing — and aims to meet all U.S. defense requirements by 2027 (https://ibn.fm/o33DQ). In addition, government programs are boosting permitting for mining and providing tax credits, grants and funding for domestic critical mineral facilities with an eye on redundant sources blunting geopolitical risk and reassuring manufacturers.

Second, shrink the bottleneck with modular refining. Concentrate is only half the journey; the true choke-point is chemical separation. This is where Ucore’s RapidSX comes into play. Unlike conventional 50-stage solvent-extraction corridors, the system arrives on modular skids and processes mixed concentrate in a fraction of the time (https://ibn.fm/xzmbc). A new $18.4 million Defense Department award — bringing total federal support to $22.4 million — is funding installation of the first commercial RapidSX line at Ucore’s Strategic Metals Complex in Alexandria, Louisiana, slated to begin commissioning next year (https://ibn.fm/OTvbq). This means that smaller, faster plants can be sited where they are needed, cutting logistics costs and giving defense contractors predictable lead times.

Third, anchor refining to magnet-making hubs. Separation alone is not enough if finished magnets still cross the Pacific. The next step aims to pair mid-stream RapidSX units with new domestic magnet factories now rising in Oklahoma, South Carolina and the Upper Midwest, which are collectively designed to cover roughly one-tenth of U.S. demand once fully ramped.

Fourth, buffer the market with stockpiles and off-take hubs. April’s executive order on critical minerals directed agencies to accelerate seabed-resource permits and evaluate a national stockpile for strategic materials, including rare-earth oxides (https://ibn.fm/mUXdY). Coupled with long-term off-take agreements encouraged by the Inflation Reduction Act, the policy aims to smooth price swings and signal guaranteed buyers to private financers. Strategic reserves and locked-in customers stabilize markets, derisk capital expenditure and prevent panic buying when headlines spike.

Finally, prove the chain with traceability and environmental, sustenance and governmental (“ESG”) standards. Regulators on both sides of the Atlantic are tightening disclosure rules. The European Union’s Critical Raw Materials Act (https://ibn.fm/qcEOo) and updated OECD guidelines require granular origin data (https://ibn.fm/BOuMT), while U.S. agencies weigh stricter reporting under Section 232 investigations (https://ibn.fm/5LGnr). Against this backdrop, technologies such as RapidSX in audit-controlled foreign-trade zones (“FTZs”) provide the verifiable documentation needed for public procurement teams, ESG compliance and green-bond markets, all in line with evolving regulation and market expectations.

Individually, none of these steps snaps China’s grip. But together, they create a network effect: diversified ore feeds enable modular refineries, those refineries feed nearby magnet plants, strategic reserves smooth demand and rigorous traceability attracts capital. “[Ucore’s] goal is to play a vital role in building a robust and independent rare earth supply chain in North America, reducing reliance on Chinese imports and fostering technological innovation,” said Ucore chair and CEO Pat Ryan (https://ibn.fm/fSE97).

For more information about Ucore Rare Metals, visit www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Small Cap News | Leave a comment

MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Poised to Play Pivotal Role in REE Supply Chain

Posted on July 16, 2025 by MissionIR

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is positioning as the U.S. takes aggressive steps to secure domestic sources of rare earth elements (“REEs”)—materials essential for defense systems, electronics and clean energy. A recent article discusses Ucore’s significant milestone in this effort, indicating the company secured an $18.4 million funding agreement from the U.S. Department of Defense (‘DoD’) to support the development of its domestic rare earth processing facility. “The project represents a major step toward American independence in the global REE supply chain, which is currently dominated by China… Ucore’s Strategic Metals Complex (‘SMC’) in Alexandria, Louisiana, aims to become a cornerstone of American rare earth processing capability. The SMC will utilize Ucore’s Proprietary RapidSX(TM) technology, which offers a more efficient and environmentally sustainable alternative to conventional solvent extraction methods… The plant is designed to separate both light and heavy REEs, including neodymium, praseodymium, dysprosium and terbium, which are crucial for permanent magnets used in electric motors and defense systems.”

To view the full article, visit https://ibn.fm/9JyXJ

About Ucore Rare Metals Inc.

Ucore is focused on rare- and critical-metal resources, extraction, beneficiation and separation technologies with the potential for production, growth and scalability. Ucore’s vision and plan is to become a leading advanced technology company, providing best-in-class metal separation products and services to the mining and mineral extraction industry. Through strategic partnerships, this plan includes disrupting the People’s Republic of China’s control of the North American REE supply chain through the near-term development of a heavy and light rare-earth processing facility in the U.S. state of Louisiana, subsequent strategic metals complexes (“SMCs”) in Canada and Alaska and the longer-term development of Ucore’s 100% controlled Bokan-Dotson Ridge Rare Heavy REE Project on Prince of Wales Island in Southeast Alaska, USA. For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Ucore Rare Metals Inc. UURAF | Leave a comment

MissionIRNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Positioning at the Forefront of Next-Gen Treatment

Posted on July 16, 2025 by MissionIR

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, is executing a dual growth strategy focused on expanding its national network of mental health clinics through its subsidiary, HOPE Therapeutics, and advancing its proprietary NMDA-based therapies toward FDA approval. HOPE recently announced plans to deploy $10.3 million in total acquisition capital to purchase clinics that provide interventional psychiatric care focused on neuroplastic therapies like transcranial magnetic stimulation (“TMS”) and ketamine. The clinics are projected to generate $15 million in 2025 revenue, with additional acquisitions in discussion that could add another $20 million. At the same time, NRx is progressing NRX-100, a preservative-free IV ketamine therapy for suicidal depression, and NRX-101, an oral therapy for bipolar depression with suicidality or akathisia—both of which have received expedited regulatory designations from the FDA.

To view the full article, visit https://ibn.fm/tdXpa

About NRx Pharmaceuticals Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the U.S. National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the U.S. FDA as part of a protocol to treat patients with acute suicidality.

NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment

SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Aligns Strategy as North American Energy Policy Shifts

Posted on July 16, 2025 by MissionIR
  • U.S. clean energy tax credits under the new Big Beautiful Bill require projects to commence construction by July 4, 2026, and complete within four years.
  • SolarBank has enough advanced-stage U.S. projects to meet this timeline, backed by a $100 million financing deal with CIM Group.
  • The company is prioritizing construction on a 97 MW portfolio in key states with interconnection and permitting progress.
  • In Canada, SolarBank is deploying battery systems in Ontario under decade-long IESO contracts and expanding in Nova Scotia’s Community Solar program.
  • Canada’s “Build, baby, build” policy push under Prime Minister Mark Carney favors developers with shovel-ready assets.
  • SolarBank is actively adjusting development and financing schedules to align with evolving incentives while managing cross-border policy risk.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., is positioning itself to navigate and benefit from rapidly evolving policy developments in both the United States and Canada. As lawmakers on both sides of the border adjust clean energy timelines, incentives, and infrastructure priorities, the solar and battery storage developer is adapting its strategy to maintain momentum and secure investor value (https://ibn.fm/KhbAn).

In the U.S., the newly enacted Big Beautiful Bill (“BBB”) sets a clear policy horizon for renewable energy developers. The legislation allows solar and battery energy storage projects to qualify for full investment tax credits (“ITCs”) if construction begins by July 4, 2026, and the projects reach commercial operation within four years. This represents a shift from earlier open-ended timelines and will likely accelerate near-term activity across the sector.

SolarBank CEO Dr. Richard Lu said the company is ready. “We have enough advanced-stage projects we can get into construction before the deadline to take advantage of the tax credits,” he noted. Crucially, a $100 million project-level financing arrangement with CIM Group will help SolarBank move forward with its 97-megawatt (“MW”) U.S. portfolio. These assets are primarily located in states where the company already controls project sites and has made permitting and interconnection progress, key hurdles that often slow renewable energy builds.

In parallel, the company is drawing on its diversified Canadian footprint to hedge against U.S. policy shifts. In Ontario, SolarBank is deploying battery energy storage systems under the province’s Long-Term RFP initiative from the Independent Electricity System Operator (“IESO”). The program offers decade-long contracts for clean, dispatchable capacity, providing long-term visibility for developers.

SolarBank also maintains a strong position in Nova Scotia’s Community Solar program, where it holds notable market share as an EPC contractor and continues to expand. These provincial programs, backed by stable regulatory support, offer an additional layer of revenue stability as the company grows.

Dr. Lu also highlighted Canada’s broader infrastructure and energy ambitions under Prime Minister Mark Carney’s “Build, baby, build” strategy, a recently launched push to accelerate infrastructure, housing, and clean energy development. “SolarBank benefits from Canada’s support to clean energy and is leading the charge to build Canada as an energy superpower,” he said.

The macro backdrop in the U.S. also remains favorable. Federal data indicates that the country must add over 206 gigawatts of new power capacity by 2030, with solar expected to provide nearly three-quarters of that supply. In the first quarter of 2025, solar and wind accounted for 98% of new generation capacity added across the nation.

According to Dr. Lu, March 2025 marked the 19th consecutive month in which solar was the largest contributor to new electrical capacity in the U.S. Falling costs and faster deployment times continue to make solar and battery storage competitive in both regulated and deregulated power markets.

As SolarBank continues to adjust its development timelines, financing structures, and construction schedules, the company is positioning itself to capture both short-term tax credit benefits and long-term value creation. With operations in two countries undergoing active energy transitions, SolarBank’s dual-market exposure may prove to be a strategic asset in the years ahead.

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward looking information. Please refer to the press release entitled “SolarBank Issues Update on Strategic Positioning Amid Shifting U.S. and Canadian Policy Landscape” for additional details on the statements, risks and assumptions.

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in SolarBank Corp. SUUN | Leave a comment

MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Highlights August as Key Window for Commercial EV Incentives Through Bollinger Motors

Posted on July 16, 2025 by MissionIR

Mullen Automotive (NASDAQ: MULN), through its subsidiary Bollinger Motors, announced that August will present a prime opportunity to purchase commercial EVs as New York’s Truck Voucher Incentive Program (NYTVIP) is set to be replenished. The program offers up to $144,000 in point-of-sale vouchers, which, when combined with the federal 45W tax credit of up to $40,000 for Class 4 vehicles, delivers major upfront savings. With federal credits expiring after September 30, 2025, Bollinger urges fleet operators to act swiftly. The Bollinger B4, an all-electric Class 4 chassis cab, qualifies for these programs and is engineered for performance, safety, and urban fleet versatility.

To view the full press release, visit https://ibn.fm/QS9l4

About Mullen Automotive Inc.

Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Mullen Automotive Inc. MULN | Leave a comment